That said, our interpretations should be viewed in the context of existing clinical, radiographic, and pathologic data that demonstrate HLA‐DRB1*15+ cases have an earlier age of onset and worse outcomes in MS [32, 33, 34]. This evidence concerns the gene HLA-DRB1 and myeloid sarcoma.